tiprankstipranks
Trending News
More News >
Hexima Ltd (AU:HXL)
ASX:HXL
Australian Market

Hexima Ltd (HXL) AI Stock Analysis

Compare
0 Followers

Top Page

AU

Hexima Ltd

(Sydney:HXL)

Rating:40Underperform
Price Target:
Hexima Ltd's stock score is primarily impacted by its poor financial performance, characterized by ongoing losses and negative cash flows. The technical analysis suggests a bearish market sentiment, while valuation metrics reflect the company's unprofitable status. The absence of earnings call data and corporate events means these factors do not influence the score. Overall, the company needs to focus on improving its financial health to enhance stock performance.

Hexima Ltd (HXL) vs. iShares MSCI Australia ETF (EWA)

Hexima Ltd Business Overview & Revenue Model

Company DescriptionHexima Ltd (HXL) is a biotechnology company focused on the research and development of plant-derived proteins for agricultural and pharmaceutical applications. The company's core products include proprietary protein-based solutions designed to enhance crop protection and improve human health. Hexima operates primarily in the agricultural biotech and pharmaceutical sectors, leveraging advanced genetic engineering technologies to deliver innovative solutions that address pressing industry needs.
How the Company Makes MoneyHexima Ltd generates revenue through the commercialization of its proprietary plant-derived protein technologies. The company's key revenue streams include the sale of licensed products to agricultural producers and pharmaceutical companies, as well as collaboration and licensing agreements with industry partners. These partnerships often involve upfront payments, milestone payments, and royalties based on product sales. Additionally, Hexima may engage in research and development collaborations that provide financial support and access to new markets. The company also benefits from government grants and subsidies aimed at promoting innovation in biotechnology.

Hexima Ltd Financial Statement Overview

Summary
Hexima Ltd faces significant financial challenges, with consistent operating losses and negative cash flows. While the balance sheet is supported by strong equity and a solid cash position, the company struggles with profitability and sustainable revenue growth. Strategic improvements in revenue generation and cost management are essential for future stability.
Income Statement
30
Negative
Hexima Ltd has experienced negative revenue growth and consistent losses over the past years. Net profit margin and other profitability metrics are negative, indicating ongoing financial challenges. The company needs to improve revenue generation and cost management to stabilize its financial health.
Balance Sheet
45
Neutral
The balance sheet shows a strong equity position with no debt, resulting in a favorable debt-to-equity ratio. However, the company has been unable to generate positive returns on equity due to persistent losses, affecting its ability to create shareholder value.
Cash Flow
40
Negative
Operating cash flow has been negative, reflecting operational inefficiencies. Although Hexima Ltd has maintained a strong cash position, free cash flow remains negative, indicating challenges in generating cash from operations despite limited capital expenditures.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue0.000.001.48M5.81M4.08M88.18K
Gross Profit0.000.001.47M5.67M3.93M-176.81K
EBITDA-549.11K-995.54K-3.08M-15.21M-10.34M-5.19M
Net Income-955.58K-933.87K-1.92M-10.02M-6.87M-3.63M
Balance Sheet
Total Assets1.68M2.27M2.96M10.75M8.58M12.71M
Cash, Cash Equivalents and Short-Term Investments1.64M2.23M2.19M3.96M3.42M9.14M
Total Debt0.000.000.000.0032.00K64.00K
Total Liabilities61.89K248.67K174.45K6.19M5.53M3.39M
Stockholders Equity1.61M2.02M2.78M4.57M3.05M9.32M
Cash Flow
Free Cash Flow-321.19K-161.90K-1.76M-9.76M-5.79M-2.10M
Operating Cash Flow-321.19K-161.90K-1.76M-9.76M-5.79M-2.10M
Investing Cash Flow48.76K98.00K38.97K-1.80K-903.00-1.74K
Financing Cash Flow0.00100.00K-3.66K10.34M7.90M1.46M

Hexima Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.01
Price Trends
50DMA
0.01
Neutral
100DMA
0.01
Negative
200DMA
0.01
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
1.67
Positive
STOCH
-150.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HXL, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, equal to the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 1.67 is Positive, neither overbought nor oversold. The STOCH value of -150.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HXL.

Hexima Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.50B0.31-61.87%2.27%17.10%1.59%
AUPYC
50
Neutral
AU$746.57M-112.97%-84.82%
AUPIQ
48
Neutral
AU$69.50M-131.55%12.53%-11.04%
AUHXL
40
Underperform
AU$2.17M-45.96%-26.67%
AUBIT
36
Underperform
AU$2.65M-119.28%64.10%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:HXL
Hexima Ltd
0.01
0.00
0.00%
AU:BIT
Biotron
0.01
-0.03
-71.79%
AU:PYC
PYC Therapeutics Limited
1.28
0.04
3.23%
AU:PIQ
Proteomics International Laboratories Ltd.
0.42
-0.48
-53.33%

Hexima Ltd Corporate Events

Hexima Limited Reports Quarterly Financials with Strategic Focus
Apr 30, 2025

Hexima Limited, an Australian company listed on the ASX, reported its financial activities for the quarter ending March 31, 2025. The company closed the quarter with a cash balance of $1.55 million, using $87,000 in net cash for operating activities, primarily for compliance costs and professional fees. The report highlights Hexima’s ongoing evaluation of strategies to benefit the company and its shareholders, with a focus on maintaining financial stability and operational efficiency.

Hexima Limited Reports Increased Losses and Decline in Net Tangible Assets
Feb 28, 2025

Hexima Limited, an Australian company, reported a 6% increase in its loss from ordinary activities after tax, amounting to $406,473 for the half-year ending December 31, 2024. The company did not declare any dividends during this period, and its net tangible assets per ordinary security decreased from 1.52 cents to 0.97 cents, indicating a decline in financial performance.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025